Specialties

A patient returns for follow-up after starting a GLP-1 receptor agonist and mentions something unexpected. Their blood glucose is improved, weight is down, and their psoriasis seems quieter. Another patient reports fewer hidradenitis flares. These anecdotes are becoming more common, raising a practical question for clinicians. Are GLP-1 therapies influencing …

A patient with type 2 diabetes finally achieves better glycemic control on a GLP-1 receptor agonist. Weight is coming down, A1C is improving, and cardiovascular risk looks more manageable. Then an unexpected comment appears at a follow-up visit. Their joints feel better. For clinicians, moments like this raise an important …

GLP-1–based therapies have quickly become a cornerstone of modern diabetes care. While most clinicians think of these agents for glucose lowering and weight loss, growing evidence suggests they may also support better blood pressure control. For patients living with diabetes and hypertension, that overlap raises an important question. Can GLP-1 …

What happens when a guideline finally reflects the complex realities of patient care? The ADA’s 2026 CKM standards aim to do just that—merging heart, kidney, and metabolic health into one actionable framework. But translating those recommendations into daily clinical decision-making isn’t always straightforward. This article walks through real-world composite cases …

Peripheral artery disease (PAD) affects millions of people with type 2 diabetes worldwide, increasing the risk of cardiovascular events and limb loss. With recent research into incretin‑based therapies, particularly glucagon‑like peptide‑1 receptor agonists (GLP‑1s), clinicians are asking whether these drugs can improve outcomes in PAD patients treated with GLP‑1s, beyond …

Menopause marks a major transition in a woman’s life, defined not only by the end of menstrual cycles but also by profound hormonal and metabolic changes. One often under‑recognized shift is the acceleration of cardiometabolic risk. Women in midlife frequently experience increased central adiposity, changes in glucose regulation, rising blood …

Glucagon‑like peptide‑1 receptor agonists (GLP‑1 RAs) have transformed type 2 diabetes management by improving blood sugar control and promoting weight loss. Yet as clinical use grows, so does interest in how GLP‑1 medications affect skeletal health — particularly their impact on bone density, remodeling, and fracture risk. This article unpacks …

The updated ADA 2026 standards represent a major shift in how clinicians approach diabetes management. Rather than focusing solely on lowering A1C, these new recommendations promote a broader, holistic strategy that integrates cardiovascular, kidney, and metabolic (CKM) risk management into everyday care. This article breaks down the key updates and …

The potential link between GLP‑1 therapies and depression has sparked growing interest among clinicians and researchers. If you’ve ever wondered whether glucagon‑like peptide‑1 (GLP‑1) receptor agonists could positively influence mood, you’re not alone. Early research suggests these medications may ease depressive symptoms by dampening inflammation and influencing brain signaling, though …

Could a diabetes medication help women with PCOS regain control of their cycles and metabolism? GLP‑1 receptor agonists, best known for treating type 2 diabetes and obesity, are showing promise for women with polycystic ovary syndrome (PCOS). These medications may support weight loss, improve insulin resistance, and even lead to …